Pacira BioSciences, Inc. has completed its merger with Viatris Inc., with the transaction closing on November 17, 2026. Under the terms of the Agreement and Plan of Merger, Pacira’s common stock was acquired for $36.50 per share in cash. The tender offer commenced on October 30, 2026, and expired on November 16, 2026. As of the expiration date, 32,929,780 shares were validly tendered, representing approximately 66.46% of the issued and outstanding shares. Following the satisfaction of the minimum condition, Purchaser accepted all validly tendered shares for payment, and the merger was consummated. Pacira will continue as the surviving corporation and will become a wholly owned subsidiary of Viatris.
In connection with the merger, the company entered into a First Supplemental Indenture regarding its 2.125% Convertible Senior Notes due 2029. The notes, with an aggregate principal amount of $287.5 million outstanding, were converted into the right to receive cash. Holders of the notes may surrender them for conversion at any time from November 17, 2026, until January 8, 2027. During this 35-day window, holders receive $1,103.8914 per $1,000 principal amount of notes converted, which includes a conversion rate of 25.2752 shares plus 4.9684 Additional Shares. After this period, the conversion rate drops to 25.2752 shares per $1,000, resulting in a payment of $922.5448 per $1,000 principal amount.
The company also terminated its Credit Agreement with Wells Fargo Bank, National Association, repaying $96,392.50 in full. Additionally, Pacira entered into unwind agreements for capped call transactions related to the 2024 note issuance, receiving cash payments from counterparties on November 17, 2026. The total funds required to pay for the shares, repay indebtedness, and pay for the merger were approximately $1.69 billion.